文献速递外周动脉疾病

股浅动脉-腘动脉外周血管介入器械注册评估的目标性能目标

Registry Assessment of Peripheral Interventional Devices objective performance goals for superficial femoral and popliteal artery peripheral vascular interventions.
PubMed 文献 · J Vasc Surg · 2020-10-17

基于血管质量倡议外周血管介入注册数据库2010年1月至2016年10月21,377例股浅动脉-腘动脉介入手术,按单纯球囊扩张、自膨式支架、斑块旋切及任何治疗分层,建立1年靶病变血运重建、大截肢及1年和4年生存率的目标性能目标,多变量分析显示严重肢体缺血是靶病变血运重建、截肢和死亡的唯一独立相关因素。

要点

  • 股浅动脉1年免于靶病变血运重建率:球囊扩张80.3%、支架83.2%、旋切83.9%、任何治疗81.9%。
  • 股浅动脉1年免于大截肢率:球囊扩张93.4%、支架95.7%、旋切95.1%、任何治疗94.8%。
  • 严重肢体缺血是靶病变血运重建、截肢和死亡的唯一独立相关因素。

核心结论

  • 股浅动脉-腘动脉证据发展研究组利用真实世界证据建立了股浅动脉-腘动脉介入的新当代目标性能目标,用于支持监管和临床决策。
  • 建议与FDA讨论针对特定试验人群细化目标性能目标,并可通过协调注册网络更新以评估长期真实世界器械性能。

研究设计与样本

  • 基于血管质量倡议外周血管介入注册数据库2010年1月至2016年10月股浅动脉-腘动脉手术共21,377例,建立间歇性跛行和严重肢体缺血的目标性能目标。
  • 目标性能目标包括1年靶病变血运重建率、大截肢率以及1年和4年生存率,按股浅动脉和腘动脉分别计算,并按单纯球囊扩张、自膨式支架、斑块旋切和任何治疗四种方式分层。
  • 结果采用未校正Kaplan-Meier分析展示。

主要发现

  • 队列包括球囊扩张7,505例、支架9,217例、斑块旋切2,510例和任何治疗21,377例;平均年龄69岁,58%为男性,79%为白人,52%有严重肢体缺血。
  • 股浅动脉1年免于靶病变血运重建率:球囊扩张80.3%、支架83.2%、旋切83.9%、任何治疗81.9%;腘动脉:球囊扩张81.3%、支架81.3%、旋切80.2%、任何治疗81.1%。
  • 股浅动脉1年免于大截肢率:球囊扩张93.4%、支架95.7%、旋切95.1%、任何治疗94.8%;腘动脉:球囊扩张90.5%、支架93.7%、旋切91.8%、任何治疗91.8%。
  • 股浅动脉4年生存率:球囊扩张76%、支架80%、旋切82%、任何治疗79%;腘动脉:球囊扩张72%、支架77%、旋切82%、任何治疗75%。
  • 多变量分析纳入患者、患肢和病变层面协变量,严重肢体缺血是靶病变血运重建、截肢和死亡的唯一独立相关因素。

临床怎么用

  • 目标性能目标可为股浅动脉-腘动脉外周器械临床试验设计提供当代基准,支持监管和临床决策。
  • 针对拟用于监管批准的研究方案,宜与FDA讨论细化目标性能目标以匹配特定试验人群。
  • 可利用协调注册网络更新目标性能目标,以评估长期真实世界器械性能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Superficial Femoral Artery-Popliteal EvidencE Development Study Group developed contemporary objective performance goals (OPGs) for peripheral vascular interventions (PVI) for superficial femoral artery (SFA)-popliteal artery disease using the Registry Assessment of Peripheral Interventional Devices. METHODS: The Society for Vascular Surgery Vascular Quality Initiative PVI registry from January 2010 to October 2016 was used to develop OPGs based on SFA-popliteal procedures (n = 21,377) for intermittent claudication and critical limb ischemia (CLI). OPGs included 1-year rates for target lesion revascularization (TLR), major amputation, and 1 and 4-year survival rates. OPGs were calculated for the SFA and popliteal arteries and stratified by four treatments: angioplasty alone (percutaneous transluminal angioplasty [PTA]), self-expanding stenting, atherectomy, and any treatment type. Outcomes were illustrated by unadjusted Kaplan-Meier analyses. RESULTS: Cohorts included PTA (n = 7505), stenting (n = 9217), atherectomy (n = 2510) and any treatment (n = 21,377). The mean age was 69 years, 58% were male, 79% were White, and 52% had CLI. The freedom from TLR OPGs at 1 year in the SFA were 80.3% (PTA), 83.2% (stenting), 83.9% (atherectomy), and 81.9% (any treatments). The freedom from TLR OPGs at 1 year in the popliteal were 81.3% (PTA), 81.3% (stenting), 80.2% (atherectomy), and 81.1% (any treatments). The freedom from major amputation OPGs at 1 year after SFA PVI were 93.4% (PTA), 95.7% (stenting), 95.1% (atherectomy), and 94.8% (any treatments). The freedom from major amputation OPG at 1 year after popliteal PVI were 90.5% (PTA), 93.7% (stenting), 91.8% (atherectomy), and 91.8%, (any treatments). The 4-year survival OPGs after SFA PVI were 76% (PTA), 80% (stenting), 82% (atherectomy), and 79% (any treatments), and for the popliteal artery were 72% (PTA), 77% (stenting), 82% (atherectomy), and 75% (any treatment). On a multivariable analysis, which included patient-level, leg-level, and lesion-level covariates, CLI was the single independent factor associated with increased TLR, amputation, and mortality. CONCLUSIONS: The Superficial Femoral Artery-Popliteal EvidencE Development OPGs define a new, contemporary benchmark for SFA-popliteal interventions using a large subset of real-world evidence to inform more efficient peripheral device clinical trial designs to support regulatory and clinical decision-making. It is appropriate to discuss proposals intended for regulatory approval with the US Food and Drug Administration to refine the OPG to match the specific trial population. The OPGs may be updated using coordinated registry networks to assess long-term real-world device performance.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Bertges DJ, White R, Cheng YC, et al. Registry Assessment of Peripheral Interventional Devices objective performance goals for superficial femoral and popliteal artery peripheral vascular interventions. J Vasc Surg. 2020. PMID: 33080324. doi:10.1016/j.jvs.2020.09.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。